The Effect of Preconception-Initiated Low-Dose Aspirin on Human Chorionic Gonadotropin-Detected Pregnancy, Pregnancy Loss, and Live Birth : Per Protocol Analysis of a Randomized Trial

What Was Tested

This randomized controlled trial paper looks at hCG (human chorionic gonadotropin).

To estimate per protocol effects of preconception-initiated LDA on pregnancy loss and live birth.

Why It Was Studied

However, this trial was subject to nonadherence, which was not taken into account by the intention-to-treat approach.

The EAGeR trial data for this study were analyzed as observational data, thus are subject to the limitations of prospective observational studies.

Who Took Part

The study group was 1227 women.

PubMed indexes the participants as adults, women only.

1227 women between the ages of 18 and 40 years who had 1 or 2 previous pregnancy losses and were attempting pregnancy.

How the Study Was Run

The design is described as randomized and placebo-controlled.

Random assignment meant chance, not the researchers, decided who got hCG (human chorionic gonadotropin) and who got the comparison, which limits bias.

The comparison arm used a placebo, so changes seen with hCG (human chorionic gonadotropin) could be set against what happens without it.

The EAGeR (Effects of Aspirin on Gestation and Reproduction) trial was used to construct a prospective cohort for a post hoc analysis.

4 university medical centers in the United States.

Adherence to LDA or placebo, assessed by measuring pill bottle weights at regular intervals during follow-up.

Primary outcomes were human chorionic gonadotropin (hCG)-detected pregnancies, pregnancy losses, and live births, determined by pregnancy tests and medical records.

What Was Measured

PubMed files the paper under topics including Abortion, Spontaneous, Anti-Inflammatory Agents, Non-Steroidal, Aspirin, Chorionic Gonadotropin, Live Birth, Medication Adherence and Preconception Care.

What This Means in Plain Language

The paper is a randomized and placebo-controlled study of hCG (human chorionic gonadotropin) in 1227 women.

With several hundred people or more, it is a fairly large study for this kind of research.

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2021 (Annals of internal medicine), a journal based in United States.

More context: the hCG (human chorionic gonadotropin) compound page, all human trials.